AKTX - Akari Therapeutics, Plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.9100
+0.0700 (+3.80%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.8400
Open1.9000
Bid0.39 x 1000
Ask1.92 x 1100
Day's Range1.8101 - 1.9100
52 Week Range1.5600 - 3.4500
Volume10,010
Avg. Volume23,575
Market Cap30.191M
Beta (3Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-1.93
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Trade prices are not sourced from all markets
  • What You Must Know About Akari Therapeutics, Plc’s (NASDAQ:AKTX) Beta Value
    Simply Wall St.28 days ago

    What You Must Know About Akari Therapeutics, Plc’s (NASDAQ:AKTX) Beta Value

    If you own shares in Akari Therapeutics, Plc (NASDAQ:AKTX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...

  • GlobeNewswire2 months ago

    Akari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate Coversin

    Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced recent developments and supporting data which underscore the differentiation of Coversin. “We are encouraged by new data that demonstrates the potential for improved patient comfort and ease of use. Alongside this focus on patient convenience we continue to develop Coversin as a differentiated treatment by means of its combined complement C5 and LTB4 inhibitory activity with early data readouts of our bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) trials expected in first quarter 2019,” said Clive Richardson, Interim Chief Executive Officer of Akari Therapeutics.

  • GlobeNewswire2 months ago

    Akari Announces Coversin Data to be Presented at 2018 Complement-Based Drug Development Summit

    Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and or leukotriene systems are implicated, today announced that PASylated Coversin data will be presented at the 2nd Annual 2018 Complement-Based Drug Development Summit in Boston, Mass. during an oral presentation by Andrew Luster, M.D., Ph.D., Chief, Division of Rheumatology, Allergy and Immunology & Director, Center for Immunology and Inflammatory Diseases Massachusetts General Hospital. Akari currently has two clinical programs open in bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) where both C5 and LTB4 are believed to be implicated.

  • How Do Analysts See Akari Therapeutics Plc (NASDAQ:AKTX) Performing In The Years Ahead?
    Simply Wall St.8 months ago

    How Do Analysts See Akari Therapeutics Plc (NASDAQ:AKTX) Performing In The Years Ahead?

    Akari Therapeutics Plc’s (NASDAQ:AKTX) latest earnings announcement in December 2017 confirmed company earnings became less negative compared to the previous year’s level as a result of recent tailwinds Below, I’veRead More...

  • Should You Buy Akari Therapeutics Plc (NASDAQ:AKTX) Now?
    Simply Wall St.8 months ago

    Should You Buy Akari Therapeutics Plc (NASDAQ:AKTX) Now?

    Akari Therapeutics Plc (NASDAQ:AKTX), a pharmaceuticals company based in United States, saw significant share price volatility over the past couple of months on the NasdaqCM, rising to the highs ofRead More...

  • ACCESSWIRE9 months ago

    Blog Exposure - Tetraphase Pharma Announced Data Presentations from IGNITE4 Study at 28th European Congress of Clinical Microbiology and Infectious Diseases

    Stock Monitor: Akari Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 16, 2018 / Active-Investors.com has just released a free research report on Tetraphase Pharma, Inc. (NASDAQ: TTPH ...

  • Thomson Reuters StreetEvents10 months ago

    Edited Transcript of AKTX earnings conference call or presentation 21-Mar-18 12:30pm GMT

    Q4 2017 Akari Therapeutics PLC Earnings Call